Combined α-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease

Human Pathology

Volumn 40, Issue 2, 2009, Pages 166-173

  Marx, Andreas ^a   Wandrey, Timo ^a   Simon, Philipp ^a   Wewer, Agatha ^a   Grob, Tobias ^a   Reichelt, Uta ^a   Minner, Sarah ^a   Simon, Ronald ^a   Spehlmann, Martina ^b   Tigges, Wolfgang ^b   Soehendra, Nib ^a   Seitz, Uwe ^a   Seewald, Stefan ^a   Izbicki, Jakob R ^a   Yekebas, Emre ^a   Kaifi, Jussuf T ^a   Mirlacher, Martina ^a   Terracciano, Luigi ^c   Fleischmann, Achim ^d   Raedler, Andreas ^b   Sauter, Guido ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Allgemeines Krankenhaus Eilbek   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

AMACR; bcl 2; Colon; Inflammatory bowel disease; p16; p504S; p53; Tissue microarray

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MYELOPEROXIDASE; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; COLON BIOPSY; COLON CARCINOMA; DIAGNOSTIC PROCEDURE; DYSPLASIA; ENTERITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION; ONCOGENE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TISSUE MICROARRAY; TUMOR GROWTH;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-BCL-2; RACEMASES AND EPIMERASES; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149109405     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.06.027     Document Type: Article

References (34)

1. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12 Suppl 1 (2006) S3-S9
2. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287 (2004) G7-G17
3. Riddell R.H., Goldman H., Ransohoff D.F., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14 (1983) 931-968
4. Bernstein C.N., Shanahan F., and Weinstein W.M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 343 (1994) 71-74
5. Ferdinandusse S., Denis S., Ijlst L., Dacremont G., Waterham H.R., and Wanders R.J. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 41 (2000) 1890-1896
6. Beach R., Gown A.M., De Peralta-Venturina M.N., et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 26 (2002) 1588-1596
7. Jiang Z., Woda B.A., Wu C.L., and Yang X.J. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol 122 (2004) 275-289
8. Rubin M.A., Zhou M., Dhanasekaran S.M., et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 (2002) 1662-1670
9. Sanderson S.O., Sebo T.J., Murphy L.M., Neumann R., Slezak J., and Cheville J.C. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol 121 (2004) 220-225
10. Wu C.L., Yang X.J., Tretiakova M., et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 35 (2004) 1008-1013
11. Dorer R., and Odze R.D. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 30 (2006) 871-877
12. Lisovsky M., Falkowski O., and Bhuiya T. Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol 37 (2006) 1601-1606
13. Harpaz N., Peck A.L., Yin J., et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 25 (1994) 1069-1074
14. Bruwer M., Schmid K.W., Senninger N., and Schurmann G. Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma. World J Surg 26 (2002) 390-396
15. Yoshida T., Matsumoto N., Mikami T., and Okayasu I. Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours. Br J Cancer 91 (2004) 1081-1088
16. King-Yin Lam A., Ong K., and Ho Y.H. Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression. Dis Colon Rectum 49 (2006) 1275-1283
17. Bronner M.P., Culin C., Reed J.C., and Furth E.E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146 (1995) 20-26
18. Sauter G., Simon R., and Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2 (2003) 962-972
19. Remmele W., and Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8 (1987) 138-140
20. Al-Kuraya K.S., Bavi P.P., Ezzat A.A., et al. Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Saudi Med J 27 (2006) 323-328
21. Yin J., Harpaz N., Tong Y., et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104 (1993) 1633-1639
22. Fogt F., Zhuang Z., Poremba C., Dockhorn-Dworniczak B., and Vortmeyer A. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Oncol Rep 5 (1998) 477-480
23. Burmer G.C., Rabinovitch P.S., Haggitt R.C., et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103 (1992) 1602-1610
24. Brentnall T.A., Crispin D.A., Rabinovitch P.S., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107 (1994) 369-378
25. Baker S.J., Preisinger A.C., Jessup J.M., et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50 (1990) 7717-7722
26. Jass J.R., Whitehall V.L., Young J., and Leggett B.A. Emerging concepts in colorectal neoplasia. Gastroenterology 123 (2002) 862-876
27. Wong N.A., Mayer N.J., MacKell S., Gilmour H.M., and Harrison D.J. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology 37 (2000) 108-114
28. Rabinovitch P.S., Dziadon S., Brentnall T.A., et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 59 (1999) 5148-5153
29. Hussain S.P., Amstad P., Raja K., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60 (2000) 3333-3337
30. Maia L., Dinis J., Cravo M., et al. Who takes the lead in the development of ulcerative colitis-associated colorectal cancers: mutator, suppressor, or methylator pathway?. Cancer Genet Cytogenet 162 (2005) 68-73
31. Dai C.Y., Furth E.E., Mick R., et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119 (2000) 929-942
32. Dursun A., Poyraz A., Suer O., Sezer C., and Akyol G. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res 7 (2001) 24-27
33. Borchard F., Heilmann K.L., Hermanek P., et al. Definition and clinical significance of dysplasia in the digestive tract. Results of a meeting of the Society of Gastroenterologic Pathology of the German Society of Pathology 25 November 1989 in Kronberg. Pathologe 12 (1991) 50-56
34. Simon R., and Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 30 (2002) 1365-1372